

## PRELIMINARY PROGRAMME

Thursday, 30<sup>th</sup> June 2022

	<b>Welcome to EuroCVP 2022 and what to expect</b>	5 min
13:30 – 14:30	<b>Inaugural Session: Understanding Clinical Trials - Three important design aspects</b>	
	Endpoint selection	15 min
	Premature Stopping	15 min
	Subgroup analyses in randomized clinical trials: Value and limitations	15 min
	Discussion	10 min
14:30 – 14:40	<i>Short break</i>	
14:40 – 15:40	<b>Session 1: Personalized Anti-Platelet Therapy in Special Populations</b>	
	Is there a need for intensified anti-platelet therapy in complex coronary interventions?	20 min
	Optimal dual anti-platelet therapy after Acute Coronary Syndrome?	20 min
	Discussion	20 min
15:40 – 16:00	<i>Coffee break &amp; Posters</i>	
16:00 – 17:00	<b>Session 2: Complex decisions and evolving fields in cardiovascular pharmacotherapy</b>	
	Prevention of microvascular thrombosis: lessons from Covid-19	10 min
	A glance to the future: noncoding RNA in cardiovascular pharmacotherapy	10 min
	Targeting the sarcomere in cardiomyopathies: myosin activator and inhibitors	10 min
	Lipid-management in complex patients: beyond vessel disease	10 min
	Discussion	20 min
17:00 – 17:10	<i>Short break</i>	
17:10 – 18:10	<b>Session 3: Challenges in the treatment of hypertension - a joint session with the ESC Council of Hypertension</b>	
	White coat and masked hypertension: what to do?	15 min
	(Apparent) "Drug-resistance": facts, mechanisms and solutions	15 min
	Tailored therapies for the different phenotypes - can additional risk factors affect the treatment choice?	15 min
	Discussion	15 min
18:10 – 19:10	Industry sponsored session	60 min

## Friday, 1<sup>st</sup> July 2022

	<b>The European Heart Journal – Cardiovascular Pharmacotherapy</b>	
08:00 – 08:55	Learn about the journal and how to get your research published	15 min
	Best Papers in EHJ CVP 2021	15 min
	Papers with the highest Altmetric index in 2021	15 min
	Best Poster Award	10 min
08:55 – 09:05	<i>Short break</i>	
	<b>Session 4: Oral Anticoagulation and anti-thrombotic therapy in patients with obstructive Coronary Artery Disease</b>	
09:05 – 10:05	Time to retire acetylsalicylic acid after PCI in AF patients?	15 min
	Myocardial Infarction in coronary ectasia patients: Anticoagulation and Anti-Platelet Therapy	15 min
	Anti-thrombotic therapy decisions in left ventricular thrombi	15 min
	Discussion	15 min
10:05 – 10:30	<i>Coffee break &amp; Posters</i>	
	<b>Session 5: Personalized Strategies for Oral Anticoagulation in older people</b>	
10:30 – 11:30	Low dose DOAC is better!	20 min
	A standard DOAC dose is preferable	20 min
	Discussion	20 min
11:30 – 11:40	<i>Short break</i>	
11:40 – 12:40	Industry sponsored session	60 min
12:40-14:00	Lunch break	
	<b>Session 6: Facing the challenge of polypharmacy in older people</b>	
14:00 – 15:00	Age-related changes in the pharmacokinetics and pharmacodynamics of cardiovascular drugs	15 min
	Inappropriate polypharmacy	15 min
	(De-)Prescribing in older people - A clinical challenge	15 min
	Discussion	15 min
15:00 – 15:10	<i>Short break</i>	

## Friday, 1<sup>st</sup> July 2022

	<b>Session 7: Antithrombotic therapy after TAVI in the older patient</b>	
15:10 – 16:10	Single antithrombotic therapy should be preferred!	20 min
	Dual antithrombotic therapy is the choice!	20 min
	Discussion	20 min
16:10-16:40	<i>Coffee break &amp; Posters</i>	
	<b>Session 8: The new era of SGLT2 Inhibitors in Cardiovascular Disease</b>	
16:40 – 17:40	The impact of SGLT2 inhibitors in the entire spectrum of Heart Failure	15 min
	Their role in Coronary Artery Disease	15 min
	SGLT2 inhibitors in Acute Heart Failure and Renal Protection	15 min
	Discussion	15 min
17:40 – 17:50	<i>Short break</i>	
	<b>Session 9: Heart Failure treatment: A Look Beyond the Guidelines – a joint session with HFA</b>	
17:50 – 18:50	Implementation of use of heart failure treatments in clinical practice: is it needed?	15 min
	Challenges to the implementation of the new HF guidelines	15 min
	Patient profiling for guiding treatment initiation and optimization	15 min
	Discussion	15 min

## Saturday, 2<sup>nd</sup> July 2022

	<b>Session 10: Cardiovascular Pharmacotherapy in Women</b>	
08:30 – 09:30	Sex disparities in response to anti-hypertensive medications: time for action	15 min
	CVD risk assessment and prevention in women with rheumatoid arthritis	15 min
	The use of cardiovascular drugs in pregnancy	15 min
	Discussion	15 min
09:30 – 09:40	<i>Short break</i>	
	<b>Session 11: New trends in management of diabetes</b>	
09:40 – 10:40	Lipids in diabetes, the new lipid lowering strategies in diabetes	15 min
	Contemporary therapy of hyperglycemia in Type 2 diabetes in CVD	15 min
	Obesity, Type-2 Diabetes Mellitus and personalized cardiovascular pharmacotherapy	15 min
	Discussion	15 min
10:40 – 11:10	<i>Coffee break &amp; Posters</i>	
	<b>Session 12: Evolving topics in Lipidology</b>	
11:10 – 12:10	Age limits for lipid lowering drugs	15 min
	Lipid-lowering drugs in patients with CKD	15 min
	New kids on the block: have novel lipid-lowering agents arrived in clinical practice?	15 min
	Discussion	15 min
12:10 – 12:20	<i>Short break</i>	
12:20 - 12:30	<b>Closing Session</b>	
		10 min